Search for: "DOW PHARMACEUTICAL SCIENCES, INC."
Results 81 - 100
of 131
Sort by Relevance
|
Sort by Date
8 Apr 2012, 8:51 pm
Stiefel Laboratories, Inc. et al. 2:12-cv-01746; filed March 20, 2012 in the District Court of New Jersey • Plaintiffs: Medicis Pharmaceutical Corp.; Dow Pharmaceutical Sciences, Inc. [read post]
20 Mar 2012, 8:54 am
Merrill Dow Pharmaceuticals, Inc., in which federal judges were directed to serve as “gatekeepers,” the Federal Judicial Center published the First Edition of the Reference Manual on Scientific Evidence, which became the leading reference source for federal judges seeking an understanding of difficult issues involving scientific testimony. [read post]
8 Mar 2012, 6:44 pm
Longoria, Merrell Dow Pharmaceuticals, Inc. v. [read post]
4 Mar 2012, 9:02 am
Merrill Dow Pharmaceuticals, Inc., 874 F.2d 307, 311-12 (5th Cir. 1989)(“Fortunately, we do not have to resolve any of the above questions [as to bias and confounding], since the studies presented to us incorporate the possibility of these factors by the use of a confidence interval. [read post]
25 Jan 2012, 6:42 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786 (1993), and discussed in Taylor v. [read post]
25 Oct 2011, 9:05 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 595 (1993), that “[e]xpert evidence can be both powerful and quite misleading because of the difficulty in evaluating it. [read post]
19 Sep 2011, 6:20 am
Merrell Dow Pharmaceuticals are meant to prevent theories based on shaky science from cluttering up court proceedings and confusing juries. [read post]
14 Aug 2011, 9:11 am
Merrell Dow Pharms., Inc., 509 U.S. 579 (1993). [read post]
8 Jul 2011, 8:52 am
MERRELL DOW PHARMACEUTICALS, INC., laying down the foundation of admissibility of scientific expert testimony. [read post]
21 Jun 2011, 4:52 am
Merrell Dow Pharmaceuticals, Inc., 509 U. [read post]
16 May 2011, 8:08 pm
[See: Laboratory Procedure Manual - Polygraph Examination (Directorate of Forensic Science, Ministry of Home Affairs, Government of India, New Delhi - 2005)]11. [read post]
7 Apr 2011, 1:16 pm
Merrell–Dow Pharmaceuticals, Inc., 523 A.2d 374, 376-79 (Pa. [read post]
18 Mar 2011, 1:28 pm
Merrell Dow Pharmaceuticals, Inc. laid down the standard for admissibility of expert testimony. [read post]
11 Mar 2011, 2:03 pm
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court ruled that federal judges may no longer use the proxy of general acceptance by specialists as the test for determining the admissibility of scientific testimony. [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
7 Feb 2011, 9:24 am
Corporate profits are strong, and the Dow is north of 12,000. [read post]
21 Nov 2010, 12:10 pm
Merrell Dow Pharmaceuticals, Inc., 959 F.2d 1349 (6th Cir.) [read post]
26 Oct 2010, 4:30 am
Merrell Dow Pharmaceuticals, decided by the Supreme Court in 1993. [read post]
24 Aug 2010, 11:34 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in which the Court instructed district courts to function as gatekeepers and permit only reliable and relevant expert testimony to be presented to the jury. [read post]
